ATPase family AAA domain-containing 3A is a novel anti-apoptotic factor in lung adenocarcinoma cells

• Published in: Journal of cell science Vol. 123; no. 7; pp. 1171 - 1180
• Main Authors: Fang, Hsin-Yuan, Chang, Chia-Ling, Hsu, Shu-Han, Huang, Chih-Yang, Chiang, Shu-Fen, Chiou, Shiow-Her, Huang, Chun-Hua, Hsiao, Yi-Ting, Lin, Tze-Yi, Chiang, I. Ping, Hsu, Wen-Hu, Sugano, Sumio, Chen, Chih-Yi, Lin, Ching-Yuang, Ko, Wen-Je, Chow, Kuan-Chih
• Format: Journal Article
• Language: English
• Published: England The Company of Biologists Limited 01.04.2010
• Subjects: Adenocarcinoma - drug therapy; Adenocarcinoma - genetics; Adenocarcinoma - metabolism; Adenocarcinoma - pathology; Adenosine Triphosphatases - genetics; Adenosine Triphosphatases - metabolism; Apoptosis - drug effects; Apoptosis - genetics; Apoptosis Regulatory Proteins - genetics; Apoptosis Regulatory Proteins - metabolism; ATPases Associated with Diverse Cellular Activities; Cisplatin - pharmacology; Disease Progression; Drug Resistance - genetics; Female; HeLa Cells; Humans; Immunohistochemistry; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - metabolism; Lung Neoplasms - pathology; Male; Membrane Proteins - genetics; Membrane Proteins - metabolism; Microscopy, Fluorescence; Mitochondria - drug effects; Mitochondria - genetics; Mitochondria - ultrastructure; Mitochondrial Proteins - genetics; Mitochondrial Proteins - metabolism; Neoplasm Staging; RNA, Small Interfering - genetics; Sequence Analysis, DNA
• ISSN: 0021-9533; 1477-9137; 1477-9137
• DOI: 10.1242/jcs.062034

AAA domain-containing 3A (ATAD3A) is a member of the AAA-ATPase family. Three forms of ATAD3 have been identified: ATAD3A, ATAD3B and ATAD3C. In this study, we examined the type and expression of ATAD3 in lung adenocarcinoma (LADC). Expression of ATAD3A was detected by reverse transcription-polymerase chain reaction, immunoblotting, immunohistochemistry and confocal immunofluorescent microscopy. Our results show that ATAD3A is the major form expressed in LADC. Silencing of ATAD3A expression increased mitochondrial fragmentation and cisplatin sensitivity. Serum deprivation increased ATAD3A expression and drug resistance. These results suggest that ATAD3A could be an anti-apoptotic marker in LADC.